Literature DB >> 17157598

Retinal pigment epithelial tear after intravitreal bevacizumab injection.

Chirag P Shah1, Jason Hsu, Sunir J Garg, David H Fischer, Richard Kaiser.   

Abstract

PURPOSE: To report two cases of a retinal pigment epithelial (RPE) tear after intravitreal bevacizumab injection for exudative age-related macular degeneration (AMD).
DESIGN: Observational case series.
METHODS: Two patients presented with occult choroidal neovascularization secondary to AMD. Both patients received intravitreal bevacizumab injections.
RESULTS: The first patient developed a RPE tear shortly after a third intravitreal bevacizumab injection. The second patient developed a RPE tear 10 days after a second intravitreal bevacizumab injection.
CONCLUSIONS: Although RPE tears may occur spontaneously as part of the natural history of exudative AMD, patients may develop visually devastating RPE tears after repeat intravitreal bevacizumab injection. Further studies are needed to determine the incidence of RPE tears after intravitreal bevacizumab injections.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17157598     DOI: 10.1016/j.ajo.2006.07.037

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  23 in total

Review 1.  Emerging therapeutic approaches in the management of retinal angiogenesis and edema.

Authors:  An Truong; Tien Y Wong; Levon M Khachigian
Journal:  J Mol Med (Berl)       Date:  2010-12-18       Impact factor: 4.599

2.  Treatment of exudative age-related macular degeneration: many factors to consider.

Authors:  Timothy W Olsen
Journal:  Am J Ophthalmol       Date:  2007-08       Impact factor: 5.258

3.  Retinal pigment epithelial tear after intravitreal ranibizumab for subfoveal CNV secondary to AMD.

Authors:  Rajendra S Apte
Journal:  Int Ophthalmol       Date:  2007-04-06       Impact factor: 2.031

4.  Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis).

Authors:  David Sarraf; Anthony Joseph; Ehsan Rahimy
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

5.  Serous retinal detachment following combined photodynamic therapy and intravitreal bevacizumab injection.

Authors:  Eui Yon Kim; Jong Wan Kim; Jun Bum Kim; Ho Min Lew
Journal:  Korean J Ophthalmol       Date:  2009-06-09

6.  Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).

Authors:  Clement K Chan; Atul Jain; Srinivas Sadda; Neeta Varshney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

7.  The role of pigment epithelial detachment in AMD with submacular hemorrhage treated with vitrectomy and subretinal co-application of rtPA and anti-VEGF.

Authors:  F Treumer; S Wienand; K Purtskhvanidze; J Roider; J Hillenkamp
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-09       Impact factor: 3.117

8.  Alterations in the intraocular cytokine milieu after intravitreal bevacizumab.

Authors:  Farzin Forooghian; Peter J Kertes; Kenneth T Eng; Elvira Agrón; Emily Y Chew
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-10       Impact factor: 4.799

9.  Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration.

Authors:  Saad Shaikh; John C Olson; Preston P Richmond
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848

10.  Massive choroidal hemorrhage after intravitreal administration of bevacizumab (Avastin) for AMD followed by controlateral sympathetic ophthalmia.

Authors:  Dimitrios Brouzas; Chryssanthi Koutsandrea; Marilita Moschos; Spiros Papadimitriou; Ioannis Ladas; Michael Apostolopoulos
Journal:  Clin Ophthalmol       Date:  2009-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.